Latest News and Press Releases

LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...

Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024...

LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...

Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s...

Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones Reiterates Commitment to Disciplined...

Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 ...

Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced,...

Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements of the Companies Act 2006...

Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination of...

Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions Announces Further Extension of Cash Runway into Q2 2025 LONDON, Aug. 31,...